Medtronic’s SPR Therapeutics deal signals a sharper move into earlier chronic pain intervention
Chronic pain care needs non-opioid options. Medtronic’s SPR Therapeutics deal tests whether temporary PNS can scale beyond niche adoption.
Nalu Medical’s wearable-powered PNS shows strong 24-month durability in COMFORT RCT
Nalu’s PNS system shows 85% responder rate at 24 months. Find out what this long-term data means for neuromodulation’s future.